Molecular Testing for Thyroid Nodules and Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 11402
Special Issue Editors
Interests: thyroid cancer; papillary thyroid carcinoma; poorly differentiated thyroid carcinoma; anaplastic thyroid carcinoma; molecular pathology; cytology; fine needle aspiration; histopathology
Special Issues, Collections and Topics in MDPI journals
Interests: surgery of the thyroid and parathyroid glands
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the last decade, molecular testing for thyroid nodules and cancers has made significant progress and is able to identify thyroid-cancer-related molecular markers which can then be applied clinically for improved decision making in different settings, representing a powerful diagnostic, prognostic, and predictive tool when used judiciously in conjunction with clinical, pathological, and radiological data. The main application of molecular testing is for thyroid nodules with indeterminate cytology (Bethesda III or IV), which represent 10–30% of thyroid nodules. For these indeterminate thyroid nodules, molecular testing is increasingly used in North America to refine the probability of cancer and to help to guide management, including surveillance for nodules that are likely benign or surgery for nodules that are likely malignant. For the latter nodules, molecular testing may also inform the extent of surgical management (lobectomy vs. total thyroidectomy) by predicting the cancer type and risk of cancer recurrence. Similarly, molecular testing may also be considered for thyroid nodules that are suspicious or positive for malignancy on cytology (Bethesda V and VI) if the results are expected to impact the management, including the timing and optimal extent of surgery. Finally, in patients with advanced thyroid cancer, including anaplastic thyroid carcinoma, molecular testing plays a critical role in identifying potential therapeutic targets allowing for the consideration of neoadjuvant targeted therapy and redefining the role and timing of surgical intervention.
On the other hand, the various molecular testing platforms for thyroid nodules are still costly and not widely available, and data demonstrating a significant clinical impact and supporting their routine use in various clinical settings are still limited.
This Special Issue will include original articles and reviews focusing on key genetic alterations in thyroid nodules and cancers and the application of molecular testing with different platforms in the various clinical settings highlighted above.
We look forward to receiving your contribution.
Dr. Marc Pusztaszeri
Dr. Richard Payne
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thyroid nodules
- thyroid cancer
- molecular testing
- cytology
- fine needle aspiration
- personalized medicine
- mutations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.